explore -WSS

explore

author：leisure time 2025-09-14 10:08:46 - browse：3

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： CDC overhauls leadership of center that led response to Covid

hotspot

WSS

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

CDC overhauls leadership of center that led response to Covid

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Genentech weighs delaying cancer therapy after drug pricing law

Newly revealed memo details efforts to keep Trump in power following election loss

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

explore

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Timeline: Special counsel's investigation into Trump's handling of classified documents

How to save PrEP access — and even expand it

The history of OxyContin, told through Purdue Pharma documents

Wildfire smoke exposes gaps in outdoor worker protections

John Green on his newest strategy for fighting tuberculosis

Psychedelics group wrestles with new pharma identity

First U.S. drug developed to treat liver disease MASH is approved

Psychedelics group wrestles with new pharma identity

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

hotspot

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Amid AI frenzy, a top HHS official's quest to create safeguards

WuXi out of biotech trade group, U.S. and China relations to blame

FDA advisers back CAR

White House drug shortages task force keeps mum with Congress

Change Healthcare outage fallout shows need for new oversight

Wikipedia

hotspot

focus

leisure time